Novo Nordisk (NVO) CEO says Trump administration's straightforward approach has made deal-making easier, via JP Morgan conference
Importance
Level 1
- Still fighting against compounded versions of Wegovy.
- Compounders of GLP-1 drugs read the consumer better than the pharma industry did, compounders of GLP-1 may have 1.5ln patients in the US.
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#JPMORGAN CHASE & CO#NOVO NORDISK A/S#NVO.US#FOREX#EQUITIES#ENERGY#EU SESSION#US SESSION#WTI#COMMODITIES#DIVERSIFIED BANKS#BANKS#BANKS (GROUP)#DXY#TRUMP#EUROPEAN EQUITIES